More than 3 million donated azithromycin treatments helped Eritrea disrupt trachoma transmission and achieve WHO validation.
The World Health Organization (WHO) has validated Eritrea as having eliminated trachoma as a public health problem, making it the 34th country globally and the 11th in the WHO African Region to achieve this milestone. The achievement reflects years of sustained national efforts, including the distribution of more than 3 million treatments of donated azithromycin from Pfizer Inc, managed by the International Trachoma Initiative (ITI), a program of The Task Force for Global Health.
Trachoma, the world's leading infectious cause of blindness, has been endemic in Eritrea for decades. Eritrea established its national trachoma program in 2006 within the Ministry of Health's National Blindness Prevention Programme. Following nationwide baseline mapping across all 58 sub-Zobas (districts), the country began implementing the WHO-recommended SAFE strategy: Surgery for trachomatous trichiasis (TT), Antibiotics to clear infection, Facial cleanliness and Environmental improvement.
Expanding access to donated antibiotics
A cornerstone of Eritrea's elimination efforts was the mass distribution of azithromycin, an antibiotic donated by Pfizer and managed by ITI. Between 2009 and 2021, Eritrea received 3,087,120 treatments of azithromycin to support its national trachoma program.






